Stock Ratings / Health Care / BCDA / financials

DYAI (33) ATYR (44) PLUR (39) PASG (51) ⌘ Pro Terminal →

BioCardia Inc. (BCDA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.93 -2.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

BioCardia Inc. (BCDA) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $14.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BCDA)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How BCDA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.2%	-$8.2M	-$7.4M	-45%
FY 2024	$4.00B	52%	-0.2%	-$7.9M	-$7.9M	-45%
FY 2023	$4.00B	52%	-0.3%	-$11.6M	-$10.0M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BCDA)

✓Walkthrough of BCDA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BCDA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.42%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.94H $0.94L $0.86C $0.93VOL 79.3K

RES: $1.48SUP: $0.87SMA50: $1.05SMA200: $1.08

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BCDA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BCDA Butterfly Map → + Track BCDA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BCDA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BCDA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BCDA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BCDA)

Health Care Rank #370 of 1016 ⚔️ DYAI vs BCDA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BCDA vs. DYAI, ATYR, PLUR, PASG)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BioCardia Inc. (BCDA) ranks #370 by composite RQD confidence (49/100, grade D) and #863 by equity capitalization ($14.0M). Within this direct 5-issuer industry benchmark cohort, BCDA leads on earnings valuation at N/A trailing P/E, while BCDA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PASG currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with BCDA at 49/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BCDA ACTIVE BioCardia Inc.	D	49/100	—	—	-35.0%	-2.26%	$14.0M	Benchmark Subject
DYAI Dyadic International Inc.	E	33/100	—	24.9%	-35.0%	-8.40%	$14.5M	/dyai-vs-bcda →
ATYR aTyr Pharma Inc.	D	44/100	—	—	-35.0%	+4.56%	$13.5M	/atyr-vs-bcda →
PLUR Pluri Inc.	D-	39/100	—	49.0%	-35.0%	-2.44%	$16.1M	/plur-vs-bcda →
PASG Passage Bio Inc.	D	51/100	—	—	-35.0%	+5.71%	$11.3M	/pasg-vs-bcda →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000925741

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioCardia Inc. (BCDA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.2M, operating cash flow of -$7.4M, and free cash flow of -$7.4M (+5.7% YoY). On the balance sheet, BCDA closed FY2025 with $3.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$8.2M	-$7.4M	-$7.4M	$3.4M	—
FY2024 (FY)	2024-12-31	$0	-$7.9M	-$7.9M	-$7.9M	$3.7M	—
FY2023 (FY)	2023-12-31	$0	-$11.6M	-$10.0M	-$10.0M	—	—

3. BCDA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BCDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, BioCardia Inc. (NASDAQ: BCDA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $0.93 (-2.26% 1D, market cap $14.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BCDA ranks #370 in composite RQD confidence.

How does BCDA compare to DYAI and ATYR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BCDA carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DYAI (Dyadic International Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $14.5M) and ATYR (aTyr Pharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, BCDA leads on earnings multiple (N/A) while BCDA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BCDA?

Per BCDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000925741), BioCardia Inc. generated $0 in revenue, -$8.2M in net income, and -$7.4M in free cash flow against $3.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BCDA trading relative to its 50-day, 200-day, and 52-week technical levels?

BCDA last traded at $0.93 (-2.26% on volume of 49,077 shares), positioning the stock -11.43% below its 50-day simple moving average ($1.05) and -13.89% below its 200-day simple moving average ($1.08). Across its 52-week range of $0.75 to $1.80, BCDA sits at the 17.1% percentile with a 14-day RSI of 37.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.05).

BCDA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is BioCardia Inc. (BCDA)?

In FY 2025 (10-K), BCDA converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: BCDA RQD Cockpit BCDA 12M Forecast BCDA Earnings & Move BCDA Dividends & DRIP BCDA Insiders & 13F BCDA Whale Options BCDA Profit Sankey BCDA News & Why